| |
|
|
COBIS tenants
We've designed COBIS to be home to a diverse group of organizations across the biotech innovation spectrum. Everything you need is at hand. And new connections happen every day. Below you can meet the tenants in COBIS, that have joined us so far.
| Acesion Pharma is a Danish biotech company founded in 2011 by scientists from NeuroSearch together with the venture funds Novo Seeds and SEED Capital Denmark II/DTU Symbion Innovation A/S. Acesion Pharma aims to develop more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. AF mainly affects the elderly population and often causes a pronounced decrease in quality of life and furthermore increases the risk of stroke. Existing drug therapies generally have a limited effect or are associated with risk of serious adverse events. Therefore, there is a considerable need for developing better and safer drugs. Inhibition of SK channels, an ion channel present in the heart and with relevance for the cardiac rhythm, constitute a novel and promising drug target for the treatment of AF. Acesion Pharma aims to develop a first-in-class SK channel inhibitor for the acute cardioversion of AF.
|
| Adenium Biotech is developing an antimicrobial peptide with bactericidal efficacy against a broad spectrum of resistant Gram negative bacteria.
|
| Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) therapeutic antibody company headquartered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of therapeutic antibodies for application in oncology, inflammation and other disease areas. CBASTM. (Cell Based Antibody Selection) is Affitech A/S's premier technology platform for the isolation of lead antibodies to cell surface targets. Several of the Company's proprietary drug candidates were generated by CBASTM.
|
| Aquaporin is working on the development of a unique and revolutionising membrane technology used for the purification of water by use of nature's own method. The target is to create the cleanest water in the world for industrial purposes and an aquaporin membrane for desalination of seawater.
|
| ARTS Biologics is developing a portfolio of bio-better gonadotrophins for Assisted Reproductive Therapy
|
| Aros Pharma is focusing on novel pharmaceuticals targeting unmet needs within pain relief, infectious disease, inflammation, respiratory diseases and immuno-suppressed patients. Projects of interest are in late pre-clinical, phase I or early phase II.
|
| BGI was founded in 1999 and has since become the largest genomic organization in the world. With a focus on research and applications in the healthcare, agriculture, conservation and bio-energy fields, BGI has a proven track record of innovative, high-profile research which has generated over 178 publications in top-tier journals such as Nature and Science.
BGI Europe and its headquarter in Copenhagen, Denmark was established in 2010, as the European branch of BGI, BGI Europe has Established partnerships and collaborations with leading academic and government research institutions, as well as global biotechnology and pharmaceutical companies.
Our goal is to make leading-edge genomics highly accessible to the global research community by leveraging industry's best technology, economies of scale and expert bioinformatics resources.
|
| Biopeople is the Danish Cluster for Health & Life Sciences and is part of the permanent national infrastructure for innovation of the Danish Agency for Science, Technology and Innovation and the Danish Council for Technology and Innovation. Biopeople comprises the vast majority of research and education institutions in Denmark, the Danish Medicines Agency, industry associations. Membership of Biopeople is open to all relevant companies. Our aim is to stimulate innovation through networking activities that brings researchers and innovation together across disciplines, sectors and public-private boundaries. |
| Cardoz is pharmaceutical company exploring new medical approaches to treat vascular diseases such as abdominal aortic aneurysm and atherosclerosis. Cardoz is developing anti-inflammatory drugs with unique properties to reduce vascular inflammation.
|
| Clinical Trial Alliance (CTA) is a part of the Capital Region of Denmark. The main objective is to establish collaborations between pharmaceutical or biotech companies and the researchers at the hospitals in the Capital Region of Denmark. Clinical Trial Alliance can assist in finding centres and identifying site management organizations for clinical trials. Furthermore, CTA helps establishing new or contacting existing research networks.
|
| DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and production in Denmark and perform common business interests in this context, both nationally and internationally.
DANISH BIOTECH members are private companies in Denmark who research, develops or produces pharmaceuticals or other products with a significant content of biotechnology (biotech companies) and their parent companies and investment funds that are active owners of biotech companies.
Membership can be obtained on www.danskbiotek.dk.
|
| EpiTherapeutics is developing novel innovative cancer drugs based on the world leading research in epigenetics conducted by Professor Kristian Helin and his group at Biotech Research & Innovation Centre (BRIC) at University of Copenhagen.
|
| Department of Research & Innovation supports an increased interaction with industry, government and university stakeholders. The support is done by concentration of expertise in business cooperation in a broad sense, including patenting and cooperation, as well as external financing, particularly in the EU area.
|
| Fischer BioConsult provides services relating to financing, business development and product development within the biotech sector. Per Fischer has more than 15 years experience from biotech, pharma and consulting, and has worked for more than 25 clients over a period of 4 years.
|
| Galecto Biotech is a newly founded company, focused on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases. The company's products target galectins, a group of proteins that play important roles in many disorders. Galecto Biotech's high potency galectin modulators may open new treatment possibilities for many patients.
|
| KIBW Concept was founded in 2001 concentrating in GMP training and Audit activities. The company expanded in 2010 also to include activities such as CMC and Due Diligence, Quality Systems and QP duties.
|
| Minerva Imaging is a CRO specializing in molecular imaging services for accelerated and efficient drug development. Services offered are in vivo pre-clinical imaging assays, design and incorporation of imaging protocols in clinical trials, and consulting.
|
| OncoNOx is a Danish biopharmaceutical company focused on developing novel anti-cancer compounds. The Company has created a range of proprietary compounds by hybridization of known drugs with nitric oxide groups. The Company is founded by a group of internationally leading scientists and biotech executives, based on the world class science conducted by Professor Ferdinando Nicoletti and co-workers.
|
| Orphazyme develops pharmaceuticals that target lysosomes. The company is dedicated to developing a novel class of therapeutics for the treatment of lysosomal storage diseases, a group of debilitating genetic disorders.
|
| Scandibiomedical is a Danish company, whose main purpose is to offer physicians and dentists unique products for the diagnosis of diseases of the oral cavity. In addition, the company develops products to treat both local and systemic diseases with oral cavity as the primary donor site.
|
| The Research Support Unit is part of the Capital Region of Denmark. Our main objective is to attract national and international funding for the region's researchers. We perform many types of tasks, for instance, advising and providing practical support for researchers writing applications.
|
| Tectra was established by the Capital Region in 2007 and is a horizontal unit for technology transfer. The unit serves all the regional hospital and psychiatry around patenting and commercialization of inventions made at the regional hospital and offer legal assistance in concluding agreements.
|
| Executive assistance, management support and traditional sales/marketing and secretarial assistance on an hourly basis.
|
| The Brain Prize will be awarded to one or more scientists who have distinguished themselves by an outstanding contribution to European brain research. The euro 1 million prize is a personal prize and will be awarded for the first time in May 2011. Awards will be followed by an extensive outreach programme organised together with the major Danish universities.
|
| Thrombologic is a small seed-capital biotech developing new discoveries from Rigshospitalet, and a leading frontier investigator to develop life-saving therapies for critically ill patients suffering from sepsis and multiple organ failure. With the backing of seed investment companies Novo Seeds and CATScience, Thrombologic's goals is to take its unique and proprietary approach from theoretical idea to experimental data — and produce enough data to support a clinical proof of concept study where both the effect and the safety of the treatment can be thoroughly tested.
|
| XENIA PHARMA is a private independent consultancy company with focus on preclinical pharmacology of new diabetes products, in particular insulin analogues and medical devices for peptide drug delivery. The aim of the company is to assist in bringing better and cheaper diabetes products to the market for the benefit of patients and society. We strive to do this through providing state of the art scientific consultancy and contract research to our clients, developers of diabetes drugs.
|
|
|
